# OPKO HEALTH, INC. (OPK) — capital_raise [announced]
Source: sec.gov · situation sit_65e8fc42117f971f19e3 · public 9781113389274134010 · retrieved 2026-08-20T14:11:16.367Z

## Overview
OPKO Health, Inc. is a pharmaceutical company that develops and commercializes healthcare products; its subsidiary EirGen Pharma Limited receives royalty payments for sales of mazdutide in China under a license agreement with Eli Lilly and Company.

On August 13, 2026, OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement and issued additional senior secured notes (the "Additional Notes") in an aggregate principal amount of $125,000,000. The Notes mature on July 17, 2044 and bear interest at the 3-month SOFR subject to a 4.0% per annum floor, plus 7.5% per annum. The Notes are secured by EirGen's royalty interest in mazdutide under a license agreement with Eli Lilly and Company, and by profit share payments received by EirGen pursuant to a profit share arrangement with Pfizer, Inc. The wholly-owned subsidiaries OPKO Biologics Ltd. and EirGen Pharma Limited serve as guarantors, and HCR Injection SPV, LLC acts as agent.

## Terms
- Counterparty: HCR Injection SPV, LLC (as agent); various purchasers · Deal value: $125.0M · Consideration: cash

## Key dates
- Announced 2026-08-14

## Timeline
- 2026-08-14 · 8-K (0001193125-26-352370): 8-K - OPKO HEALTH, INC. — *OPKO Health, Inc. is a pharmaceutical company that develops and commercializes healthcare products; its subsidiary EirGen Pharma Limited receives royalty payments for sales of mazdutide in China under a license agreement with Eli Lilly and Company.* On August 13, 2026, OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement and issued additional senior secured notes (the "Additional Notes") in an aggregate principal amount of $125,000,000. The Notes mature on July 17, 2044 and bear interest at the 3-month SOFR subject to a 4.0% per annum floor, plus 7.5% per annum. The Notes are secured by EirGen's royalty interest in mazdutide under a license agreement with Eli Lilly and Company, and by profit share payments received by EirGen pursuant to a profit share arrangement with Pfizer, Inc. The wholly-owned subsidiaries OPKO Biologics Ltd. and EirGen Pharma Limited serve as guarantors, and HCR Injection SPV, LLC acts as agent.
  https://www.sec.gov/Archives/edgar/data/944809/0001193125-26-352370.txt

## Citations
- 0001193125-26-352370 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526352370